117753-06-7

Basic information

• Product Name: 2-(4-cyanophenyl)acetamide
• Synonyms: 2-(4-cyanophenyl)acetamide
• CAS NO: 117753-06-7
• Molecular Weight: 160.175
• Mol File: 117753-06-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-(4-cyanophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-cyanophenyl)acetamide(117753-06-7)
• EPA Substance Registry System: 2-(4-cyanophenyl)acetamide(117753-06-7)

Safety Data

• Hazardous Substances Data: 117753-06-7(Hazardous Substances Data)

Usage

Organic compound

Yes

Commonly used in

Pharmaceutical research and development

Building block for

Synthesis of various drugs and pharmaceuticals

Physical form

White solid

Solubility

Soluble in organic solvents

Melting point

180-182 °C

Synthetic routes

+ Reaction of 4-cyanobenzoyl chloride with methylamine
+ Reaction of 4-cyanobenzaldehyde with hydroxylamine in the presence of an acid catalyst

Pharmacological activities

+ Anti-inflammatory
+ Antipyretic
+ Analgesic

Value in pharmaceutical synthesis

Valuable intermediate

Upstream product

• 876-31-3 4-(cyanomethyl)benzonitrile 
• 5462-71-5 4-cyanophenylacetic acid 
• 62044-37-5 4-cyanophenylacetic acid chloride 
• 67-56-1 methanol 
• 874-86-2 4-cyanobenzyl chloride 

Downstream Products

• 861393-91-1 N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dimethylpropyl]-2-(4-cyanophenyl)acetamide 
• 1388210-98-7 2-(4-{5-[1-methyl-5-({[5-(trifluoromethyl)pyridin-2-yl]oxy}methyl)-1H-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}phenyl)acetamide 
• 1388214-12-7 (4-{5-[1-methyl-5-({[5-(trifluoromethyl)pyridin-2-yl]oxy}methyl)-1H-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}phenyl)acetonitrile 
• 191868-20-9 (R)-N-[[4-(Aminocarbonylmethyl)phenyl)methyl]-N₅-[amino-(nitroimino)methyl]-N₂-(diphenylacetyl)-ornithinamide 
• 191871-42-8 (R,S)-N-[[4-(aminocarbonylmethyl)phenyl]methyl]-N₂-[[(3,4-dichlorophenyl)amino]carbonyl]-ornithinamide 
• 1596336-55-8 2-(4-cyanophenyl)-N-(6-methoxy-4-{[7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl}pyridin-2-yl)acetamide 
• 181466-81-9 2-[4-(aminomethyl)phenyl]acetamide 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain

We disclose the design of a novel series of cyanoguanidines that are potent (IC50 ? 10-100 nM) and selective (≥100-fold) P2X7 receptor antagonists against the other P2 receptor subtypes such as the P2Y2, P2X4, and P2X3. We also found that these P2X7 antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 μmol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X7 receptors in neuropathic pain and therefore a potential use of P2X7 antagonists as novel therapeutic tools for the treatment of this type of pain.

AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM

The invention relates to new amino acid derivatives of general formula (I), wherein B, T, Z, Y, V and n are defined as in claim 1, the tautomers, diastereomers and enantiomers thereof, the mixtures thereof and the salts thereof, particularly their physiologically acceptable salts with inorganic or organic acids or bases which have valuable pharmacological properties, particularly selective NPY-antagonist properties, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.